Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MedImmune

Lucid Group is building its data analytics capability

Lucid Group is building a new data analytics capability into its teams with the appointment of Darren Selmes as its new analyst. This appointment signals the start of a stronger...

Lucid Group Communications Limited

- PMLiVE

EU may seek legal action against AstraZeneca following vaccine supply cuts

EU supply issues for the AZ vaccine started in January 2021

- PMLiVE

Lucid Group promotes Clare Reynolds to Director of Business Development and Commercial Integration

As Lucid continues to evolve, its people have remained at the heart of its success. Clare Reynolds has played a key part in Lucid’s journey for nearly 12 years, during...

Lucid Group Communications Limited

- PMLiVE

Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab

Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4,000 participants

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

AZ showcases data for next-generation PARP inhibitor AZD5305

Early preclinical data presented at virtual American Association of Cancer Research meeting

Lucid Group Bolster its Senior Leadership Team

Lucid Group are delighted to welcome Jo Troman to the role of Managing Partner for team Origins. Jo has a wealth of industry experience from both client and agency sides....

Lucid Group Communications Limited

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine

Early-stage trial will enrol 30 healthy volunteers aged 18-40

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links